Ikarian Capital, LLC Dbv Technologies S.A. Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	BUY	$1.22 - $1.77 $8,331 - $12,087	6,829 Added 2.2%	316,939 $1.05 Million
Q3 2021 Nov 15, 2021	SELL	$4.71 - $5.92 $59,440 - $74,710	-12,620 Reduced 3.91%	310,110 $3.11 Million
Q1 2021 May 17, 2021	SELL	$2.75 - $6.57 $97,900 - $233,892	-35,600 Reduced 9.93%	322,730 $3.39 Million
Q4 2020 Feb 12, 2021	BUY	$1.38 - $3.01 $267,168 - $582,736	193,600 Added 117.53%	358,330 $1.9 Million
Q2 2020 Aug 14, 2020	SELL	$3.74 - $6.28 $237,052 - $398,045	-63,383 Reduced 27.79%	164,730 $723,000

Q1 2020 May 15, 2020	BUY	$2.33 - $12.98 $357,829 - $1.99 Million	153,575 Added 206.04%	228,113 $894,000
Q4 2019 Jan 31, 2020	BUY	$6.75 - $11.15 $503,131 - $831,098	74,538 New	74,538 $798,000

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $2.52B
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.